SETD2 and nonpapillary renal cell carcinoma: Similar to what have been described in ccRCC and pRCC10, 11, 20, 15, 16, 17, mutations in chromatin modulation genes are relatively frequent in uRCC, although none of which (for example, SETD2 and BAP1) was found to be significantly associated with clinical outcomes in this cohort.